The UK and US have signed a key trade agreement that will keep no levies on UK medicine exports being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to increase funding on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these crucial goods will remain at nothing for a timeframe of the next three years.
This agreement follows previous warnings to hike import taxes on branded drug products, with figures mentioned reaching one hundred percent.
"This deal with the United Kingdom strengthens the global environment for new treatments and introduces much-needed equity to transatlantic pharmaceutical trade," a release said.
Commercial Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest goods shipped to the America, which is easily the largest buyer for major companies like GSK and AstraZeneca.
Statistics reveal that in the year leading up to September, the UK sold drugs worth billions to the US. This figure represented nearly one-fifth of British export trade in that period.
"This deal safeguards employment, boosts funding and paves the way for the UK to establish itself as a global hub for life sciences," a minister stated.
Detailed UK Commitments
The deal includes several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it considers new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage drug companies must pay back to the NHS to prevent overspending will be limited at 15%. In the past, repayments topped twenty percent.
Recent Tensions
The pact comes amid a protracted tension between the sector and the ministers over medicine costs and approval rates.
The disagreement were intensified by arguments that US patients were charged several times more for the identical medicines than people in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been announced toward American operations.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
